Key Points
- CFO Jason Davis purchased 70,000 shares of FibroBiologics on March 2 at an average price of $0.41 per share for a total of $28,700, increasing his position from zero to 70,000 shares (SEC filing).
- The stock trades near $0.39 with a market cap of about $26.3 million and a 52-week range of $0.22–$1.53; the company reported Q earnings of ($0.03) EPS, beating estimates of ($0.09).
- Analyst coverage is mixed—two Buys and one Sell—with recent price-target cuts (e.g., $15→$7 and $4), and a MarketBeat consensus rating of "Hold" and target price of $5.50.
FibroBiologics Inc. (NASDAQ:FBLG - Get Free Report) CFO Jason Davis purchased 70,000 shares of the stock in a transaction on Monday, March 2nd. The stock was acquired at an average price of $0.41 per share, for a total transaction of $28,700.00. Following the completion of the purchase, the chief financial officer directly owned 70,000 shares in the company, valued at approximately $28,700. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.
FibroBiologics Price Performance
Shares of NASDAQ FBLG opened at $0.39 on Wednesday. The business has a 50-day moving average of $0.29 and a 200-day moving average of $0.38. The stock has a market capitalization of $26.31 million, a price-to-earnings ratio of -0.93 and a beta of -0.69. FibroBiologics Inc. has a fifty-two week low of $0.22 and a fifty-two week high of $1.53.
FibroBiologics (NASDAQ:FBLG - Get Free Report) last posted its quarterly earnings results on Tuesday, February 24th. The company reported ($0.03) earnings per share for the quarter, beating analysts' consensus estimates of ($0.09) by $0.06. On average, sell-side analysts expect that FibroBiologics Inc. will post -0.53 EPS for the current year.
Analyst Ratings Changes
A number of research analysts have recently commented on FBLG shares. D. Boral Capital decreased their price objective on shares of FibroBiologics from $15.00 to $7.00 and set a "buy" rating for the company in a research report on Wednesday, February 25th. HC Wainwright cut their target price on shares of FibroBiologics to $4.00 and set a "buy" rating for the company in a research note on Thursday, February 26th. Finally, Weiss Ratings reissued a "sell (e+)" rating on shares of FibroBiologics in a research report on Thursday, January 22nd. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, FibroBiologics currently has a consensus rating of "Hold" and a consensus target price of $5.50.
Check Out Our Latest Report on FBLG
Institutional Trading of FibroBiologics
Several hedge funds have recently added to or reduced their stakes in FBLG. AQR Capital Management LLC acquired a new position in shares of FibroBiologics in the first quarter valued at about $29,000. XTX Topco Ltd boosted its stake in shares of FibroBiologics by 160.0% in the second quarter. XTX Topco Ltd now owns 45,945 shares of the company's stock valued at $29,000 after buying an additional 28,276 shares during the period. Ethos Financial Group LLC grew its position in FibroBiologics by 100.0% during the second quarter. Ethos Financial Group LLC now owns 48,848 shares of the company's stock worth $30,000 after buying an additional 24,424 shares in the last quarter. AMG National Trust Bank acquired a new position in FibroBiologics in the 4th quarter valued at $31,000. Finally, Jane Street Group LLC acquired a new position in FibroBiologics in the 4th quarter valued at $34,000.
FibroBiologics Company Profile
(
Get Free Report)
FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc was incorporated in 2021 and is based in Houston, Texas.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
